



Universiteit
Leiden
The Netherlands

Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants

Santen, S. van; Out, J.J.; Zoutman, W.H.; Quint, K.D.; Willemze, R.; Vermeer, M.H.; Tensen, C.P.

Citation

Santen, S. van, Out, J. J., Zoutman, W. H., Quint, K. D., Willemze, R., Vermeer, M. H., & Tensen, C. P. (2021). Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants. *Biochemistry And Biophysics Reports*, 26. doi:10.1016/j.bbrep.2021.101007

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3280110>

Note: To cite this publication please use the final published version (if applicable).

Table 2. Detailed characteristics of included CTCL patients and controls, IL31 serum detectability and relation with pruritus

No.	CTCL subtype	E / A	TNMB stage	Pruritus?	Pruritus degree	Pruritus information	IL31 Serum concentration (pg/mL)	IL31 Serum concentration (pg/mL) in consecutive samples (time between sampling in months)	qPCR data?
1	SS	A	IV	+	Severe	MR	1.39	0.31(13), ND(55) ^a	n/p
2	SS	A	IV	+	Severe	MR	1.07	-	LOW
3	SS	A	IV	+	Severe	MR	0.68	0.37(31), ND(43) ^a	ND
4	SS	A	IV	+	Severe	MR	0.57	-	n/p
5	FMF	E	IB	+	Moderate	MR	0.43	-	n/p
6	FMF	A	III	+	Severe	MR	0.41	ND(133)	LOW
7	FMF	A	III	+	Moderate	MR	0.40	-	n/p
8	SS	A	IV	+	Severe	MR	0.27	-	n/p
9	FMF	E	IA	+	Moderate	VAS (5.9)	0.21	-	n/p
10	FMF	A	IIB	+	Moderate	MR	0.20	-	LOW
11	SS	A	IV	+	Severe	MR	0.20	0.26(55), ND(25) ^a	ND
12	MF	E	IB	+	Severe	VAS (9.2)	ND	-	n/p
13	SS	A	IV	+	Severe	VAS (7.4)	ND	-	n/p
14	FMF	E	IB	+	Severe	VAS (7.0)	ND	ND(1)	n/p
15	SS	A	IV	+	Severe	VAS (6.8)	ND	-	n/p
16	SS	A	IV	+	Moderate	VAS (5.4)	ND	-	n/p
17	MF	A	IIB	+	Moderate	VAS (4.9)	ND	-	n/p
18	MF	E	IA	+	Moderate	VAS (4.9)	ND	-	n/p
19	FMF	E	IB	+	Moderate	VAS (4.5)	ND	-	n/p
20	SS	A	IV	+	Moderate	VAS (4.0)	ND	ND(15)	n/p
21	FMF	A	IIB	+	Moderate	VAS (3.8)	ND	-	n/p
22	FMF	A	IIB	+	Moderate	VAS (3.3)	ND	ND(3), ND(55)	n/p
23	MF	E	IA	-	Low	VAS (2.0)	ND	-	n/p
24	MF	E	IB	-	Low	VAS (1.7)	ND	-	n/p
25	SS	A	IV	-	Low	VAS (1.5)	ND	-	n/p

26	MF	E	IA	-	Low	VAS (0.6)	ND	-	n/p
27	FMF	E	IA	-	Low	VAS (0.5)	ND	-	n/p
28	FMF	E	IA	-	Low	VAS (0.3)	ND	-	n/p
29	MF	E	IA	-	Low	VAS (0.1)	ND	-	n/p
30	MF	E	IB	-	Low	VAS (0.1)	ND	-	n/p
31	FMF	A	IIB	-	No	VAS (0.0)	ND	-	n/p
32	FMF	E	IA	-	No	VAS (0.0)	ND	-	n/p
33	MF	E	IB	-	No	VAS (0.0)	ND	-	n/p
34	MF	E	IA	-	No	VAS (0.0)	ND	-	n/p
35	MF	E	IB	-	No	VAS (0.0)	ND	-	n/p
36	MF	A	IIB	-	No	VAS (0.0)	ND	-	n/p
37	MF	A	IIB	-	No	VAS (0.0)	ND	-	n/p
38	SS	A	IV	+	Severe	MR	ND	-	n/p
39	SS	A	IV	+	Severe	MR	ND	-	n/p
40	FMF	A	IIB	+	Severe	MR	ND	-	ND
41	FMF	A	IV	+	Severe	MR	ND	-	n/p
42	SS	A	IV	+	Moderate	MR	ND	ND(14) ^b	n/p
43	SS	A	IV	+	Moderate	MR	ND	ND(20) ^c	n/p
44	SS	A	IV	+	Moderate	MR	ND	ND(33) ^d	n/p
45	SS	A	IV	+	Moderate	MR	ND	-	n/p
46	FMF	E	IA	+	Moderate	MR	ND	-	n/p
47	FMF	E	IIA	+	Moderate	MR	ND	-	n/p
48	FMF	A	IIB	+	Moderate	MR	ND	-	LOW
49	FMF	A	IV	+	Moderate	MR	ND	-	n/p
50	FMF	A	IV	+	Moderate	MR	ND	-	n/p
51	FMF	A	IIB	-	No	MR	ND	-	n/p
52	MF	A	IV	-	No	MR	ND	-	n/p
53	MF	A	IIB	-	No (Painful skin)	MR	ND	-	LOW (2x)
54	MF	A	IIB	-	No	MR	ND	-	n/p
C	AD	N.A.	-	+	Severe	VAS (6.8)	1.06	-	-
C	AD	N.A.	-	+	Severe	VAS (6.7)	1.21	-	-

C	AD	N.A.	-	+	Severe	VAS (8.0)	ND	-	-
C	AD	N.A.	-	+	Severe	VAS (8.6)	ND	-	-
C	AD	N.A.	-	+	Severe	VAS (8.7)	ND	-	-
C	Healthy	N.A.	-	-	-	-	ND	-	-
C	Healthy	N.A.	-	-	-	-	ND	-	-
C	Healthy	N.A.	-	-	-	-	ND	-	-
C	Healthy	N.A.	-	-	-	-	ND	-	-

A: advanced-stage disease (according to TNMB staging system stages IIB-IV are considered advanced-stage disease); AD: atopic dermatitis; CTCL: cutaneous T cell lymphoma; C: control sample; E: early-stage disease (stages IA-IIA are considered early-stage disease); FMF: folliculotropic mycosis fungoides; mo: months; LOW: lowly expressed (Cq>31); MF: mycosis fungoides, MR: (retrieved from) medical records; N.A. not applicable; ND: not detected; No.: patient number; n/p: not performed; qPCR quantitative polymerase chain reaction; SS: Sézary syndrome; TNMB: tumor node metastasis blood staging system; VAS: visual analogue scale (VAS <3,3 was considered low; VAS 3,3-6,6 was considered moderate, VAS >6,6 was considered severe).

^a *In these patients IL31 could be detected in one of two follow-up samples, while these patients continued to suffer from a similar degree of pruritus.*

^b *At follow up sampling, this SS patient had no complaints of pruritus (VAS score of 0.0).*

^c *At follow up sampling, this SS patient suffered from minimal complaints of pruritus (VAS score of 2.0).*

^d *At follow up sampling, this SS patient had no complaints of pruritus (retrieved from medical record).*